| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 135.55% | EF Hutton | → $11 | Reiterates | Buy → Buy |
| 06/26/2023 | 135.55% | EF Hutton | $11 → $11 | Maintains | Buy |
| 05/25/2023 | 135.55% | EF Hutton | → $11 | Assumes | → Buy |
| 05/18/2023 | — | HC Wainwright & Co. | Initiates Coverage On | → Neutral | |
| 03/21/2023 | 135.55% | EF Hutton | → $11 | Reiterates | → Buy |
| 02/15/2023 | 135.55% | EF Hutton | → $11 | Maintains | Buy |
| 11/01/2022 | 135.55% | EF Hutton | → $11 | Initiates Coverage On | → Buy |
| 03/11/2022 | 670.88% | HC Wainwright & Co. | $34 → $36 | Maintains | Buy |
| 11/02/2021 | 628.05% | HC Wainwright & Co. | $32 → $34 | Maintains | Buy |
| 10/07/2021 | 585.22% | HC Wainwright & Co. | → $32 | Initiates Coverage On | → Buy |
| 07/28/2020 | 413.92% | Colliers Securities | → $24 | Initiates Coverage On | → Buy |
What is the target price for Lantern Pharma (LTRN)?
The latest price target for Lantern Pharma (NASDAQ: LTRN) was reported by EF Hutton on August 10, 2023. The analyst firm set a price target for $11.00 expecting LTRN to rise to within 12 months (a possible 135.55% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lantern Pharma (LTRN)?
The latest analyst rating for Lantern Pharma (NASDAQ: LTRN) was provided by EF Hutton, and Lantern Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Lantern Pharma (LTRN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lantern Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lantern Pharma was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
Is the Analyst Rating Lantern Pharma (LTRN) correct?
While ratings are subjective and will change, the latest Lantern Pharma (LTRN) rating was a reiterated with a price target of $0.00 to $11.00. The current price Lantern Pharma (LTRN) is trading at is $4.67, which is within the analyst's predicted range.